News

Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...
Novo Nordisk is in the lead, but not alone. Obesity doctors say they are gearing up for demand, predicted to be high. Some ...
After declaring Chapter 11 bankruptcy in May of 2025, once-giant WeightWatchers (rebranded to WW beginning in 2018) admitted ...
CVS is set to drop Zepbound as a medicine, but will continue to carry other popular weight loss drugs instead.
Researchers say GLP-1 medicines might be able to help with migraines.
A recent survey highlighted a widespread lack of understanding about the much-publicised GLP-1 weight-loss medications ...
A large network meta-analysis ranked eight GLP-1 receptor agonists for glycemic, weight, and safety outcomes in adults with ...
There’s no doubt that GLP-1 drugs like Ozempic have been revolutionary — although the benefits do sometimes come with some ...
The rise of Ozempic and weight-loss drugs is a convenient excuse for the fashion industry and retailers to cut back on plus-size clothing options.
A Cleveland Clinic study shows that semaglutide and tirzepatide – injectable GLP-1 drugs for obesity – produce smaller weight loss in a real-world setting because patients discontinue ...
Several top nutrition and obesity organizations provided the first unified guidelines for helping patients manage their ...
Kate Farms has launched high-protein plant-based shakes to tackle "critical nutrition gaps" from GLP-1 use, its first product ...